CA1208560A - Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma - Google Patents
Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucomaInfo
- Publication number
- CA1208560A CA1208560A CA000427097A CA427097A CA1208560A CA 1208560 A CA1208560 A CA 1208560A CA 000427097 A CA000427097 A CA 000427097A CA 427097 A CA427097 A CA 427097A CA 1208560 A CA1208560 A CA 1208560A
- Authority
- CA
- Canada
- Prior art keywords
- pgf2
- eye
- iop
- alpha
- eyes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 57
- 208000010412 Glaucoma Diseases 0.000 title claims abstract description 15
- 150000002066 eicosanoids Chemical class 0.000 title abstract description 19
- 206010030043 Ocular hypertension Diseases 0.000 title abstract description 12
- 230000000699 topical effect Effects 0.000 claims abstract description 35
- 241000288906 Primates Species 0.000 claims abstract description 18
- 239000000203 mixture Substances 0.000 claims abstract description 16
- PXGPLTODNUVGFL-YNNPMVKQSA-N prostaglandin F2alpha Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O PXGPLTODNUVGFL-YNNPMVKQSA-N 0.000 claims abstract description 13
- 125000005907 alkyl ester group Chemical group 0.000 claims abstract description 7
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 claims description 93
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 14
- -1 PGF2.alpha. isobutyl ester Chemical class 0.000 claims description 10
- 235000019483 Peanut oil Nutrition 0.000 claims description 7
- 239000000312 peanut oil Substances 0.000 claims description 7
- 206010020772 Hypertension Diseases 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000002480 mineral oil Substances 0.000 claims description 3
- 235000010446 mineral oil Nutrition 0.000 claims description 3
- PJDMFGSFLLCCAO-NVRZHKMMSA-N PGF2alpha methyl ester Chemical group CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)OC PJDMFGSFLLCCAO-NVRZHKMMSA-N 0.000 claims description 2
- FPABVZYYTCHNMK-YNRDDPJXSA-N PGF2alpha isopropyl ester Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)OC(C)C FPABVZYYTCHNMK-YNRDDPJXSA-N 0.000 claims 1
- 125000003473 lipid group Chemical group 0.000 claims 1
- 230000003287 optical effect Effects 0.000 claims 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 abstract description 51
- 229960002986 dinoprostone Drugs 0.000 abstract description 49
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 abstract description 49
- 229940094443 oxytocics prostaglandins Drugs 0.000 abstract description 37
- 150000003180 prostaglandins Chemical class 0.000 abstract description 37
- 210000001508 eye Anatomy 0.000 description 152
- 230000004410 intraocular pressure Effects 0.000 description 85
- 241000282326 Felis catus Species 0.000 description 36
- 241001465754 Metazoa Species 0.000 description 24
- 238000002474 experimental method Methods 0.000 description 20
- 230000003547 miosis Effects 0.000 description 18
- 230000001179 pupillary effect Effects 0.000 description 18
- 230000000694 effects Effects 0.000 description 17
- 239000000243 solution Substances 0.000 description 16
- 230000002354 daily effect Effects 0.000 description 15
- 230000007423 decrease Effects 0.000 description 15
- 241000282560 Macaca mulatta Species 0.000 description 14
- 230000009467 reduction Effects 0.000 description 14
- 230000001077 hypotensive effect Effects 0.000 description 13
- 230000004044 response Effects 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 241000283973 Oryctolagus cuniculus Species 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 210000002159 anterior chamber Anatomy 0.000 description 9
- 210000001747 pupil Anatomy 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 9
- BFUUJUGQJUTPAF-UHFFFAOYSA-N 2-(3-amino-4-propoxybenzoyl)oxyethyl-diethylazanium;chloride Chemical compound [Cl-].CCCOC1=CC=C(C(=O)OCC[NH+](CC)CC)C=C1N BFUUJUGQJUTPAF-UHFFFAOYSA-N 0.000 description 8
- 241000282693 Cercopithecidae Species 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 150000002148 esters Chemical class 0.000 description 8
- 208000001953 Hypotension Diseases 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- 150000004702 methyl esters Chemical class 0.000 description 7
- 239000003604 miotic agent Substances 0.000 description 7
- 241000894007 species Species 0.000 description 7
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 208000021822 hypotensive Diseases 0.000 description 6
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 6
- 230000009545 invasion Effects 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 230000003389 potentiating effect Effects 0.000 description 6
- 230000002035 prolonged effect Effects 0.000 description 6
- 241000282709 Aotus trivirgatus Species 0.000 description 5
- 206010027646 Miosis Diseases 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 229940087458 alcaine Drugs 0.000 description 5
- 210000001742 aqueous humor Anatomy 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 206010052127 Anterior chamber flare Diseases 0.000 description 4
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 4
- 206010043087 Tachyphylaxis Diseases 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 230000001886 ciliary effect Effects 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 229930003347 Atropine Natural products 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 208000007950 Ocular Hypotension Diseases 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 239000002220 antihypertensive agent Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 3
- 229960000396 atropine Drugs 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 210000004087 cornea Anatomy 0.000 description 3
- 210000003560 epithelium corneal Anatomy 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 229960000905 indomethacin Drugs 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 229960003299 ketamine Drugs 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 210000004789 organ system Anatomy 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 229960001371 proparacaine hydrochloride Drugs 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000001525 retina Anatomy 0.000 description 3
- 235000017550 sodium carbonate Nutrition 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 2
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 2
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 description 2
- 210000002164 blood-aqueous barrier Anatomy 0.000 description 2
- 230000004420 blood-aqueous barrier Effects 0.000 description 2
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000000795 conjunctiva Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000010339 dilation Effects 0.000 description 2
- BORBLDJNKYHVJP-FXBDTBDDSA-N dolichodial Chemical compound C[C@H]1CC[C@H](C(=C)C=O)[C@@H]1C=O BORBLDJNKYHVJP-FXBDTBDDSA-N 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000000622 irritating effect Effects 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 229940023490 ophthalmic product Drugs 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229960001416 pilocarpine Drugs 0.000 description 2
- 230000036515 potency Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 210000003786 sclera Anatomy 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002691 topical anesthesia Methods 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 229960000281 trometamol Drugs 0.000 description 2
- 108010051913 15-hydroxyprostaglandin dehydrogenase Proteins 0.000 description 1
- 102100030489 15-hydroxyprostaglandin dehydrogenase [NAD(+)] Human genes 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 241001553178 Arachis glabrata Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 101000692466 Bos taurus Prostaglandin F synthase 2 Proteins 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010009185 Ciliary muscle spasm Diseases 0.000 description 1
- 208000006069 Corneal Opacity Diseases 0.000 description 1
- 101100400880 Cricetulus griseus PGY2 gene Proteins 0.000 description 1
- 241000283715 Damaliscus lunatus Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 206010018307 Glaucoma and ocular hypertension Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- ZAHXYMFVNNUHCP-UHFFFAOYSA-N Naphazoline nitrate Chemical compound O[N+]([O-])=O.C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 ZAHXYMFVNNUHCP-UHFFFAOYSA-N 0.000 description 1
- JWOLLWQJKQOEOL-UHFFFAOYSA-N OOOOOOOOOOOOO Chemical compound OOOOOOOOOOOOO JWOLLWQJKQOEOL-UHFFFAOYSA-N 0.000 description 1
- RSDOPYMFZBJHRL-UHFFFAOYSA-N Oxotremorine Chemical compound O=C1CCCN1CC#CCN1CCCC1 RSDOPYMFZBJHRL-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 206010037538 Pupils unequal Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 101150063830 abcB4 gene Proteins 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 239000003732 agents acting on the eye Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 208000001239 anisocoria Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000004082 barrier epithelial cell Anatomy 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000001710 bronchial artery Anatomy 0.000 description 1
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 1
- 229960004484 carbachol Drugs 0.000 description 1
- 239000002561 chemical irritant Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 210000003683 corneal stroma Anatomy 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000007257 deesterification reaction Methods 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- MUCZHBLJLSDCSD-UHFFFAOYSA-N diisopropyl fluorophosphate Chemical compound CC(C)OP(F)(=O)OC(C)C MUCZHBLJLSDCSD-UHFFFAOYSA-N 0.000 description 1
- 229960001342 dinoprost Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000004406 elevated intraocular pressure Effects 0.000 description 1
- 230000004890 epithelial barrier function Effects 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000004996 female reproductive system Anatomy 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229940015418 ketaset Drugs 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 230000004446 light reflex Effects 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000004297 night vision Effects 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- DZUXGQBLFALXCR-CDIPTNKSSA-N prostaglandin F1alpha Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1CCCCCCC(O)=O DZUXGQBLFALXCR-CDIPTNKSSA-N 0.000 description 1
- 239000002089 prostaglandin antagonist Substances 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 210000000857 visual cortex Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US374,165 | 1982-05-03 | ||
| US06/374,165 US4599353A (en) | 1982-05-03 | 1982-05-03 | Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1208560A true CA1208560A (en) | 1986-07-29 |
Family
ID=23475591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000427097A Expired CA1208560A (en) | 1982-05-03 | 1983-04-29 | Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma |
Country Status (7)
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8263054B2 (en) | 2002-02-04 | 2012-09-11 | Allergan, Inc. | Method of enhancing hair growth |
| US8758733B2 (en) | 2002-02-04 | 2014-06-24 | Allergan, Inc. | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists |
| US8859616B2 (en) | 2011-01-21 | 2014-10-14 | Allergan, Inc. | Compounds and methods for enhancing hair growth |
| EP1225168B2 (en) † | 1988-09-06 | 2015-01-21 | Pfizer Health AB | Prostaglandin-F-2 alpha derivative for the treatment of glaucoma or ocular hypertension |
| US9149484B2 (en) | 2009-11-09 | 2015-10-06 | Allergan, Inc. | Compositions and methods for stimulating hair growth |
| US9216183B2 (en) | 2002-02-04 | 2015-12-22 | Allergan, Inc. | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists |
| US9750750B2 (en) | 2009-11-09 | 2017-09-05 | Allergan, Inc. | Compositions and methods for stimulating hair growth |
Families Citing this family (204)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2053458T3 (es) * | 1986-03-13 | 1994-08-01 | Univ Columbia | Utilizacion de prostaglandinas a, b y c y derivados de las mismas, para el tratamiento de la hipertension ocular y glaucoma. |
| US4883819A (en) * | 1986-07-31 | 1989-11-28 | The Trustees Of Columbia University In The City Of New York | Use of A, B and C prostaglandins and derivatives thereof to treat ocular hypertension and glaucoma |
| AU602509B2 (en) * | 1986-03-13 | 1990-10-18 | Trustees Of Columbia University In The City Of New York, The | Use of A,B and C prostaglandins and derivatives therof to treat ocular hypertension and glaucoma |
| US4824857A (en) * | 1986-05-16 | 1989-04-25 | Yasumasa Goh | Use of prostaglandin D2 -active substances |
| US4822819A (en) * | 1986-11-07 | 1989-04-18 | Alcon Laboratories, Inc. | Use of trimoprostil and derivatives in glaucoma therapy |
| US4822820A (en) * | 1986-11-24 | 1989-04-18 | Alcon Laboratories, Inc. | Use of tri-methyl PG-F2 a and derivatives in glaucoma therapy |
| ZA88963B (en) * | 1987-02-27 | 1989-11-29 | Allergan Inc | Prostaglandins useful for lowering intraocular pressure |
| ATE76750T1 (de) * | 1987-04-03 | 1992-06-15 | Univ Columbia | Anwendung eines prostaglandins in mischung mit einem adrenergischen blocker zur verminderung des augen-innendruckes. |
| US4952581A (en) * | 1987-04-03 | 1990-08-28 | The Trustees Of Columbia University In The City Of New York | Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocular pressure |
| GB8710780D0 (en) * | 1987-05-07 | 1987-06-10 | Scras | Opthalmological application of eicosapentaenoic acid |
| ATE82499T1 (de) * | 1987-09-18 | 1992-12-15 | R Tech Ueno Ltd | Okulare hypotensivagenzien. |
| US5212200A (en) * | 1987-09-18 | 1993-05-18 | R-Tech Ueno, Ltd. | Ocular hypotensive agents |
| US5151444B1 (en) * | 1987-09-18 | 1999-07-06 | R Tech Ueno Ltd | Ocular hypotensive agents |
| US5166178B1 (en) * | 1987-09-18 | 1998-07-21 | R Tech Ueno Ltd | Ocular hypotensive agents |
| US6420422B1 (en) | 1987-09-18 | 2002-07-16 | Sucampo Pharmaceuticals, Inc. | Ocular hypotensive agents |
| US5236907A (en) * | 1988-10-01 | 1993-08-17 | R-Tech Ueno Ltd. | Ocular hypotensive agents |
| EP0310322A3 (en) * | 1987-09-30 | 1990-10-10 | Allergan, Inc | Use of thromboxane b2 to constrict the pupil and lower intraocular pressure |
| SE8703854D0 (sv) * | 1987-10-07 | 1987-10-07 | Pharmacia Ab | Prostaglandinderivat for behandling av glaukom eller okuler hypertension |
| US5565492A (en) * | 1988-07-18 | 1996-10-15 | Alcon Laboratories, Inc. | Prostaglandin combinations in glaucoma therapy |
| EP1300149A3 (en) * | 1988-09-06 | 2003-05-14 | Pharmacia Aktiebolag | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
| US5321128A (en) * | 1988-09-06 | 1994-06-14 | Kabi Pharmacia Ab | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
| US6187813B1 (en) * | 1990-04-10 | 2001-02-13 | Pharmacia & Upjohn Aktiebolag | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
| US5296504A (en) * | 1988-09-06 | 1994-03-22 | Kabi Pharmacia | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
| EP0580268B1 (en) * | 1988-10-01 | 1998-01-14 | R-Tech Ueno Ltd. | Ocular hypotensive agents |
| US5194429A (en) * | 1988-10-01 | 1993-03-16 | K.K. Ueno Seiyaku Oyo Kenkyujo | Ocular hypotensive agents |
| US5271939A (en) * | 1988-10-03 | 1993-12-21 | Alcon Laboratories, Inc. | Pharmaceutical compositions and methods of treatment to prevent and treat corneal scar formation produced by laser irradiation |
| US5360611A (en) * | 1988-10-03 | 1994-11-01 | Alcon Laboratories, Inc. | Pharmaceutical compositions and methods of treatment of the cornea following ultraviolet laser irradiation |
| US4927846A (en) * | 1988-11-23 | 1990-05-22 | Allergan, Inc. | Intraocular pressure reducing 1,11-lactone prostaglandins |
| US5114971A (en) * | 1989-05-15 | 1992-05-19 | Kabi Pharmacia Ab | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
| AU635294B2 (en) * | 1989-07-27 | 1993-03-18 | Allergan, Inc. | Intraocular pressure reducing 9,11-diacyl prostaglandins |
| US5034413A (en) * | 1989-07-27 | 1991-07-23 | Allergan, Inc. | Intraocular pressure reducing 9,11-diacyl prostaglandins |
| CA2021316C (en) * | 1989-07-27 | 2000-10-24 | Ming Fai Chan | Intraocular pressure reducing 11-acyl prostaglandins |
| US4994274A (en) * | 1989-07-27 | 1991-02-19 | Allergan, Inc. | Intraocular pressure reducing 11,15-diacyl prostaglandins and method of using |
| CA2020254A1 (en) * | 1989-07-27 | 1991-01-28 | Ming F. Chan | Intraocular pressure reducing 9, 15-diacyl prostaglandins |
| US5028624A (en) * | 1989-07-27 | 1991-07-02 | Allergan, Inc. | Intraocular pressure reducing 9,15-diacyl prostaglandins |
| DE69108326T2 (de) * | 1990-03-08 | 1995-07-27 | Shionogi & Co., Ltd., Osaka | 15-deoxyprostaglandinderivat. |
| US5292754A (en) * | 1990-03-08 | 1994-03-08 | Shionogi & Co., Ltd. | Treatment for hypertension or glaucoma in eyes |
| US5011856A (en) * | 1990-03-12 | 1991-04-30 | Allergan, Inc. | Use of prostaglandin F3 α as an ocular hypotensive agent |
| CA2076023A1 (en) * | 1990-03-19 | 1991-09-20 | David Frederick Woodward | Use of 5-trans prostaglandin f as an ocular hypotensive agent |
| DE69116224T2 (de) * | 1990-05-22 | 1996-05-23 | Ueno Seiyaku Oyo Kenkyujo Kk | Behandlung von intraokularem Druck mit einer synergischen Kombination |
| EP0458589B1 (en) * | 1990-05-22 | 1995-01-18 | R-Tech Ueno Ltd. | Treatment of ocular hypertension with an ocular synergistic combination |
| US5238961A (en) * | 1990-06-14 | 1993-08-24 | Allergan, Inc. | Pgf 1-alcohols and their use as ocular hypotensives |
| US5270049A (en) * | 1990-11-09 | 1993-12-14 | Allergan, Inc. | 2-decarboxyl-2-aminoalkyl-prostaglandins as ocular hypotensives |
| US5262437A (en) * | 1990-12-10 | 1993-11-16 | Allergan, Inc. | Homo-prostaglandin derivatives as ocular hypotensives |
| US5288754A (en) * | 1992-02-04 | 1994-02-22 | Allergan, Inc. | Polar C-1 esters of prostaglandins |
| US5972991A (en) | 1992-09-21 | 1999-10-26 | Allergan | Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
| US5688819A (en) * | 1992-09-21 | 1997-11-18 | Allergan | Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
| US5352708A (en) * | 1992-09-21 | 1994-10-04 | Allergan, Inc. | Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
| US5834498A (en) * | 1992-09-21 | 1998-11-10 | Allergan | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
| US5468778A (en) * | 1992-09-24 | 1995-11-21 | Allergan, Inc. | Method of lowering intraocular pressure by administering a pharmaceutical composition containing 7-(5-substituted cyclopentyl) and 7-(5-substituted-cyclopentenyl) 5-heptenoic acids and derivatives |
| ATE153855T1 (de) * | 1992-10-13 | 1997-06-15 | Alcon Lab Inc | Zusammensetzungen zur behandlung von glaukoma die prostaglandine und clonidinderivate enthalten |
| US5332730A (en) * | 1992-10-16 | 1994-07-26 | Allergan, Inc. | Azido derivatives of cyclopentane heptanoic or heptenoic acid |
| US5385945A (en) * | 1992-10-21 | 1995-01-31 | Allergan, Inc. | 7-(5-substituted cyclopentyl) and (5-substituted cyclopentenyl) heptyl alcohols, heptylamines and heptanoic acid amides, and method of lowering intraocular pressure in the eye of a mammal by administration of these novel compounds |
| US5328933A (en) * | 1992-10-28 | 1994-07-12 | Allergan, Inc. | Cyclopentane heptenylnitro and heptanylnitro-2-aliphatic or aryl aliphatic derivatives and homologues |
| US5574066A (en) * | 1992-10-28 | 1996-11-12 | Allergan | Intraocular pressure reducing 15-acyl prostaglandins |
| US5312842A (en) * | 1992-10-30 | 1994-05-17 | Allergan, Inc. | Cyclopentane heptenylsulfinylalkyl and heptanylsulfinylalkyl-2-aliphatic or aryl aliphatic derivatives |
| US6124353A (en) * | 1992-11-12 | 2000-09-26 | Allergan Sales, Inc. | Method of treating ocular hypertension with 8-epi prostaglandins |
| KR950000664A (ko) * | 1993-06-14 | 1995-01-03 | 우에노 도시오 | 신규한 13,14-디히드로-피지에프 2 베타(PGF2β) 및 이의 이소프로필 에스테르 |
| US6184250B1 (en) | 1993-08-03 | 2001-02-06 | Alcon Laboratories, Inc. | Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension |
| US5510383A (en) * | 1993-08-03 | 1996-04-23 | Alcon Laboratories, Inc. | Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension |
| US5387608A (en) * | 1993-08-17 | 1995-02-07 | Allergan, Inc. | Cyclopentane(ene) heptanoic or cyclopentane(ene) heptenoic acid, 2-hydrocarbyl sulfonamidomethyl and derivatives thereof as therapeutic agents |
| US5624893A (en) * | 1993-10-14 | 1997-04-29 | Alcon Laboratories, Inc. | Pharmaceutical compositions and methods of treatment of the cornea following laser irradiation |
| US5476872A (en) * | 1993-10-18 | 1995-12-19 | Allergan, Inc. | 1,11-diesters of prostaglandin-F2α having a polar ester group at C-1 |
| US5486540A (en) * | 1993-10-28 | 1996-01-23 | Allergan, Inc. | Cyclopentane heptanoic or heptenoic acid, 2-arylalkyl or arylalkenyl and derivatives as therapeutic agents |
| US6462077B1 (en) * | 1993-12-28 | 2002-10-08 | Allergan, Inc. | Thromboxane ligands without blood clotting side effects |
| US5545665A (en) * | 1993-12-28 | 1996-08-13 | Allergan | Cyclopentane(ene) heptenoic or heptanoic acids and derivatives thereof useful as therapeutic agents |
| US5416106A (en) * | 1993-12-28 | 1995-05-16 | Allergan, Inc. | 7-[carboxyalkyl or alkenyl]-6-[alkyl or alkenyl]3-oxo-2,4-dioxobicyclo-[3.2.1] octane and derivatives thereof |
| US5650431A (en) * | 1993-12-28 | 1997-07-22 | Allergan | Thromboxane ligands without blood clotting side effects |
| US5741812A (en) * | 1993-12-28 | 1998-04-21 | Allergan | Thromboxane ligands without blood clotting side effects |
| US5462968A (en) * | 1994-01-19 | 1995-10-31 | Allergan, Inc. | EP2 -receptor agonists as agents for lowering intraocular pressure |
| US5516796A (en) * | 1994-03-24 | 1996-05-14 | Kabi Pharmacia Ab | Thioprostaglandins and -prostaglandin-like compounds and therapeutic uses thereof |
| US6294563B1 (en) | 1994-10-27 | 2001-09-25 | Allergan Sales, Inc. | Combinations of prostaglandins and brimonidine or derivatives thereof |
| US5869079A (en) * | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
| US20060280774A1 (en) * | 1995-06-02 | 2006-12-14 | Allergan, Inc. | Compositions and methods for treating glaucoma |
| US5767153A (en) * | 1995-06-07 | 1998-06-16 | Insite Vision Incorporated | Sustained release emulsions |
| US6172054B1 (en) | 1995-06-15 | 2001-01-09 | Alcon Laboratories, Inc. | Combination therapy for lowering and controlling intraocular pressure |
| US5698598A (en) * | 1995-08-04 | 1997-12-16 | Allergan | EP2 -receptor agonists as agents for lowering intraocular pressure |
| US6441047B2 (en) | 1995-11-17 | 2002-08-27 | Alcon Manufacturing Ltd.. | Combination therapy for treating glaucoma |
| EP0861079A1 (en) * | 1995-11-17 | 1998-09-02 | Alcon Laboratories, Inc. | Combination therapy for treating glaucoma |
| US5814660A (en) * | 1995-12-22 | 1998-09-29 | Alcon Laboratories, Inc. | 9-oxa prostaglandin analogs as ocular hypotensives |
| US5866602A (en) * | 1995-12-22 | 1999-02-02 | Alcon Laboratories, Inc. | Keto-substituted tetrahydrofuran analogs of prostaglandins as ocular hypotensives |
| US5700835A (en) * | 1995-12-22 | 1997-12-23 | Alcon Laboratories, Inc. | 3-Oxa-D-prostaglandins for lowering IOP |
| AU7680096A (en) * | 1995-12-22 | 1997-07-17 | Alcon Laboratories, Inc. | Combinations of dp and fp type prostaglandins for lowering iop |
| US5658897A (en) * | 1996-04-08 | 1997-08-19 | Allergan | Cyclopentane(ene) heptanoic or cyclopentane(ene) heptenoic acid, 2-hydrocarbyl phosphinyloxyalkyl or phosphonamidoalkyl as therapeutic agents |
| US5735275A (en) * | 1996-06-13 | 1998-04-07 | Ballou; Jon | Tonometer utilizing hydraulic pressure |
| US6680339B2 (en) | 1996-11-12 | 2004-01-20 | Alcon Manufacturing, Ltd. | 15-fluoro prostaglandins as ocular hypotensives |
| ATE202557T1 (de) | 1996-11-12 | 2001-07-15 | Alcon Lab Inc | 15-fluoro-prostaglandine als augendrucksenkende mittel |
| CA2269853A1 (en) | 1996-11-12 | 1998-05-22 | Paul W. Zinke | Use of cis-.delta.4 analogs of prostaglandins as ocular hypotensives |
| JP4397973B2 (ja) | 1997-02-04 | 2010-01-13 | ジョンストン， マーレイ エイ． | 瞼の毛髪の成長を刺激するための局所的組成物 |
| AU725677B2 (en) * | 1997-05-09 | 2000-10-19 | Mount Sinai School Of Medicine Of The City University Of New York, The | 8-iso-prostaglandins for glaucoma therapy |
| EP0998277A1 (en) * | 1997-05-30 | 2000-05-10 | Merck & Co., Inc. (a New Jersey corp.) | Ophthalmic compositions for treating ocular hypertension |
| US5877211A (en) * | 1997-11-21 | 1999-03-02 | Allergan | EP2 receptor agonists as neuroprotective agents for the eye |
| AU1709699A (en) | 1997-12-22 | 1999-07-12 | Alcon Laboratories, Inc. | 13-oxa prostaglandins for the treatment of glaucoma and ocular hypertension |
| US6156785A (en) * | 1998-01-23 | 2000-12-05 | Merck Sharp & Dohme B.V. | Method for increasing oxygen tension in the optic nerve and retina |
| EP1000619A3 (en) * | 1998-06-23 | 2002-07-24 | Pfizer Products Inc. | Method for treating glaucoma |
| CA2337399A1 (en) * | 1998-07-21 | 2000-02-03 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
| US6417228B1 (en) | 1998-11-02 | 2002-07-09 | Alcon Manufacturing, Ltd.. | 13-Aza prostaglandins for the treatment of glaucoma and ocular hypertension |
| US6096783A (en) * | 1998-12-15 | 2000-08-01 | Alcon Laboratories, Inc. | Cyclobutane prostaglandin analogues as ocular hypotensive agents |
| US6211226B1 (en) | 1998-12-17 | 2001-04-03 | Alcon Laboratories, Inc. | 11-Aza prostaglandins for the treatment of glaucoma and ocular hypertension |
| WO2000051980A1 (en) | 1999-03-05 | 2000-09-08 | The Procter & Gamble Company | C16 unsaturated fp-selective prostaglandins analogs |
| US6548535B2 (en) | 2000-01-18 | 2003-04-15 | Merck & Co., Inc. | Method for treating ocular hypertension |
| CA2396319A1 (en) * | 2000-01-18 | 2001-07-26 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
| US20010046982A1 (en) * | 2000-02-01 | 2001-11-29 | Maxey Kirk M. | Internal 1, 15-lactones of fluprostenol and related prostaglandin F2a analogs and their use in the treatment of glaucoma and intraocular hypertension |
| US20020037914A1 (en) * | 2000-03-31 | 2002-03-28 | Delong Mitchell Anthony | Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins |
| US20020172693A1 (en) * | 2000-03-31 | 2002-11-21 | Delong Michell Anthony | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
| US20020013294A1 (en) | 2000-03-31 | 2002-01-31 | Delong Mitchell Anthony | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
| US6726918B1 (en) | 2000-07-05 | 2004-04-27 | Oculex Pharmaceuticals, Inc. | Methods for treating inflammation-mediated conditions of the eye |
| EP1341541A4 (en) * | 2000-11-16 | 2004-11-17 | Alcon Mfg Ltd | COMBINATION THERAPY FOR LOWERING AND CONTROLLING THE EYE PRESSURE |
| DE60114229T2 (de) * | 2000-11-29 | 2006-07-06 | Allergan, Inc., Irvine | Verhinderung von transplantatabstossung im auge |
| KR100875908B1 (ko) * | 2001-04-19 | 2008-12-26 | 테이카 세이야쿠 가부시키가이샤 | 약제 및 약제 키트 |
| GB0112699D0 (en) | 2001-05-24 | 2001-07-18 | Resolution Chemicals Ltd | Process for the preparation of prostglandins and analogues thereof |
| TWI298257B (en) | 2001-05-31 | 2008-07-01 | Allergan Inc | Hypotensive lipid and timolol compositions and methods of using same |
| US20040254230A1 (en) * | 2001-12-03 | 2004-12-16 | Ogidigben Miller J. | Method for treating ocular hypertension |
| TW200305424A (en) | 2002-01-29 | 2003-11-01 | Santen Pharmaceutical Co Ltd | Glaucoma-treating agent comprising bunazosin and prostaglandin |
| WO2003077845A2 (en) * | 2002-03-15 | 2003-09-25 | Merck & Co., Inc. | Compositions and methods for treating glaucoma and ocular hypertension |
| AU2003233731A1 (en) * | 2002-06-06 | 2003-12-22 | Xavier Billot | 1,5-disubstituted imidazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of eye and bone diseases |
| JP2005532363A (ja) * | 2002-06-14 | 2005-10-27 | メルク エンド カムパニー インコーポレーテッド | 高眼圧を治療するための眼用組成物 |
| AU2003247533B2 (en) * | 2002-06-17 | 2008-09-18 | Merck & Co., Inc. | Novel maxi-k channel blockers, methods of use and process for making the same |
| CA2488845A1 (en) * | 2002-06-17 | 2003-12-24 | Merck & Co., Inc. | Opthalmic compositions containing selective m1 muscarinic agonists for treating ocular hypertension |
| US20050239787A1 (en) * | 2002-06-17 | 2005-10-27 | Goetz Michael A | Novel maxi-k channel blockers, methods of use and process for making the same |
| US6864282B2 (en) * | 2002-08-05 | 2005-03-08 | Allergan, Inc. | 9,11-cycloendoperoxide pro-drugs of prostaglandin analogues for treatment of ocular hypertension and glaucoma |
| AU2003258433A1 (en) * | 2002-08-28 | 2004-03-19 | Merck Frosst Canada Ltd | Oxazolidin-2-one and thiazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of glaucoma |
| KR101160780B1 (ko) * | 2002-08-29 | 2012-06-27 | 산텐 세이야꾸 가부시키가이샤 | Ｒｈｏ 키나아제 억제제 및 프로스타글란딘류를 포함하는 녹내장 치료제 |
| US20060167081A1 (en) * | 2002-10-25 | 2006-07-27 | Xavier Billot | Ep4 receptor agonists |
| US20050048099A1 (en) | 2003-01-09 | 2005-03-03 | Allergan, Inc. | Ocular implant made by a double extrusion process |
| US20040216749A1 (en) * | 2003-01-23 | 2004-11-04 | Hosheng Tu | Vasomodulation during glaucoma surgery |
| US6949518B1 (en) | 2003-06-25 | 2005-09-27 | Pao-Hsien Chu | Methods for treating macular degeneration with topiramate |
| US20050119262A1 (en) * | 2003-08-21 | 2005-06-02 | Pharmacia Corporation | Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent |
| US7235586B2 (en) * | 2003-09-09 | 2007-06-26 | Allergan, Inc. | Cyclopentane heptan(ene)oic acid, 2-thiocarbamoyloxy and 2-carbamoyloxy compounds as therapeutic agents |
| US20050101582A1 (en) * | 2003-11-12 | 2005-05-12 | Allergan, Inc. | Compositions and methods for treating a posterior segment of an eye |
| US20070224278A1 (en) * | 2003-11-12 | 2007-09-27 | Lyons Robert T | Low immunogenicity corticosteroid compositions |
| US20050250737A1 (en) * | 2003-11-12 | 2005-11-10 | Allergan, Inc. | Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods |
| US20090148527A1 (en) * | 2007-12-07 | 2009-06-11 | Robinson Michael R | Intraocular formulation |
| US20060141049A1 (en) * | 2003-11-12 | 2006-06-29 | Allergan, Inc. | Triamcinolone compositions for intravitreal administration to treat ocular conditions |
| US7186744B2 (en) * | 2003-11-13 | 2007-03-06 | Allergan, Inc. | Prostamides for the treatment of glaucoma and related diseases |
| GB0329620D0 (en) * | 2003-12-22 | 2004-01-28 | Pharmagene Lab Ltd | EP2 receptor agonists |
| WO2005072701A1 (en) | 2004-01-20 | 2005-08-11 | Allergan, Inc. | Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid |
| US8455656B2 (en) | 2004-04-30 | 2013-06-04 | Allergan, Inc. | Kinase inhibitors |
| US8147865B2 (en) * | 2004-04-30 | 2012-04-03 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
| US7589057B2 (en) | 2004-04-30 | 2009-09-15 | Allergan, Inc. | Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems |
| BRPI0510485A (pt) | 2004-04-30 | 2007-11-13 | Allergan Inc | implantes inibidores de tirosina cinase intravìtreos biodegradáveis |
| US8591885B2 (en) * | 2004-04-30 | 2013-11-26 | Allergan, Inc. | Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems |
| US20050244461A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Controlled release drug delivery systems and methods for treatment of an eye |
| US7993634B2 (en) * | 2004-04-30 | 2011-08-09 | Allergan, Inc. | Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods |
| US20050244472A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Intraocular drug delivery systems containing excipients with reduced toxicity and related methods |
| US9498457B2 (en) | 2004-04-30 | 2016-11-22 | Allergan, Inc. | Hypotensive prostamide-containing biodegradable intraocular implants and related implants |
| US20050244465A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Drug delivery systems and methods for treatment of an eye |
| US20050244478A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Anti-excititoxic sustained release intraocular implants and related methods |
| US8119154B2 (en) | 2004-04-30 | 2012-02-21 | Allergan, Inc. | Sustained release intraocular implants and related methods |
| US20060182781A1 (en) * | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Methods for treating ocular conditions with cyclic lipid contraining microparticles |
| US20050244463A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
| US8673341B2 (en) * | 2004-04-30 | 2014-03-18 | Allergan, Inc. | Intraocular pressure reduction with intracameral bimatoprost implants |
| US20050244471A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Estradiol derivative and estratopone containing sustained release intraocular implants and related methods |
| US20070059336A1 (en) * | 2004-04-30 | 2007-03-15 | Allergan, Inc. | Anti-angiogenic sustained release intraocular implants and related methods |
| US20050244462A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Devices and methods for treating a mammalian eye |
| US7771742B2 (en) | 2004-04-30 | 2010-08-10 | Allergan, Inc. | Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods |
| US7799336B2 (en) | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
| US8722097B2 (en) | 2004-04-30 | 2014-05-13 | Allergan, Inc. | Oil-in-water method for making polymeric implants containing a hypotensive lipid |
| US20050244469A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
| US20050244466A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Photodynamic therapy in conjunction with intraocular implants |
| US8425929B2 (en) * | 2004-04-30 | 2013-04-23 | Allergan, Inc. | Sustained release intraocular implants and methods for preventing retinal dysfunction |
| US20050244458A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular neuropathies |
| WO2006017347A2 (en) * | 2004-07-12 | 2006-02-16 | Allergan, Inc. | Opthalmic compositions and methods for treating ophthalmic conditions |
| ATE412400T1 (de) * | 2004-11-09 | 2008-11-15 | Novagali Pharma Sa | Öl-in-wasser-emulsion mit niedriger konzentration des kationischen mittels und positivem zetapotential |
| WO2010102078A1 (en) | 2009-03-04 | 2010-09-10 | Allergan, Inc. | Enhanced bimatoprost ophthalmic solution |
| US7851504B2 (en) * | 2005-03-16 | 2010-12-14 | Allergan, Inc. | Enhanced bimatoprost ophthalmic solution |
| CN102293774A (zh) | 2005-03-31 | 2011-12-28 | 旭硝子株式会社 | 前列腺素F2α衍生物的应用 |
| WO2006112313A1 (ja) * | 2005-04-13 | 2006-10-26 | Ube Industries, Ltd. | インダゾール誘導体を有効成分として含む網膜神経細胞保護剤 |
| US20070178138A1 (en) * | 2006-02-01 | 2007-08-02 | Allergan, Inc. | Biodegradable non-opthalmic implants and related methods |
| CA2681668C (en) * | 2006-03-23 | 2014-04-01 | Michael S. Singer | Compositions comprising prostaglandin f2-alpha analogs and methods for reducing body fat |
| US20070298073A1 (en) * | 2006-06-23 | 2007-12-27 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
| US8802128B2 (en) | 2006-06-23 | 2014-08-12 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
| CN101495452B (zh) * | 2006-07-28 | 2012-04-25 | 辉瑞产品公司 | Ep2激动剂 |
| NZ573964A (en) * | 2006-07-28 | 2010-11-26 | Pfizer Prod Inc | isopropyl [3-({[4-(1H-pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)-amino}methyl)phenoxy]acetate, a prostaglandin E2 receptor agonist (EP2), useful in lower intraocular pressure thereby treating glaucoma |
| BRPI0715974A2 (pt) * | 2006-08-23 | 2014-09-16 | Allergan Inc | Tiazolidinonas, oxazolidinonas substituídas terapêuticas, e compostos relacionados. |
| US8969415B2 (en) | 2006-12-01 | 2015-03-03 | Allergan, Inc. | Intraocular drug delivery systems |
| US7911053B2 (en) * | 2007-04-19 | 2011-03-22 | Marvell World Trade Ltd. | Semiconductor packaging with internal wiring bus |
| EP2077104A1 (en) | 2008-01-02 | 2009-07-08 | Novagali Pharma SA | Micellar compositions with ophtalmic applications |
| US20090170944A1 (en) * | 2008-01-02 | 2009-07-02 | Novagali Pharma Sa | Ophthalmic micellar compositions with enhanced stability |
| US20090169629A1 (en) * | 2008-01-02 | 2009-07-02 | Novagali Pharma Sa | Micellar compositions with ophthalmic applications |
| EP2077105A1 (en) | 2008-01-02 | 2009-07-08 | Novagali Pharma SA | Ophthalmic Micellar Compositions with Enhanced Stability |
| US8722739B2 (en) * | 2008-10-29 | 2014-05-13 | Novaer Holdings, Inc. | Amino acid salts of prostaglandins |
| US8623918B2 (en) | 2008-10-29 | 2014-01-07 | Novaer Holdings, Inc. | Amino acid salts of prostaglandins |
| US20100204335A1 (en) * | 2008-12-01 | 2010-08-12 | Allergan, Inc. | Kit and composition for eyelash growth |
| US20110293549A1 (en) | 2009-02-03 | 2011-12-01 | Athena Cosmetics, Inc. | Composition, method and kit for enhancing hair |
| EP2228058A1 (en) | 2009-03-04 | 2010-09-15 | Novagali Pharma S.A. | Anionic oil-in-water emulsion containing prostaglandins and uses thereof |
| US20100247606A1 (en) * | 2009-03-25 | 2010-09-30 | Allergan, Inc. | Intraocular sustained release drug delivery systems and methods for treating ocular conditions |
| WO2010116270A1 (en) | 2009-04-10 | 2010-10-14 | Pfizer Inc. | Ep2/4 agonists |
| EP2421981B1 (en) * | 2009-04-23 | 2013-08-14 | Neurotech USA, Inc. | Cell lines that produce prostaglandin f2 alpha (pgf2a) and uses thereof |
| US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
| EP2389939A1 (en) | 2010-05-28 | 2011-11-30 | Novagali Pharma S.A. | Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions |
| US9522153B2 (en) | 2009-12-22 | 2016-12-20 | Allergan, Inc. | Compositions and methods for lowering intraocular pressure |
| US9061034B2 (en) | 2010-07-29 | 2015-06-23 | Allergan, Inc. | Preservative free bimatoprost and timolol solutions |
| PL2598118T3 (pl) | 2010-07-29 | 2019-01-31 | Allergan, Inc. | Roztwory bimatoprost i tymolol bez środków konserwujących |
| WO2012021107A2 (en) | 2010-08-12 | 2012-02-16 | Nanyang Technological University | A liposomal formulation for ocular drug delivery |
| JP5778781B2 (ja) | 2011-01-19 | 2015-09-16 | トポカイン セラピューティックス， インコーポレイテッド | 代謝症候群を治療する方法および組成物 |
| KR20140010028A (ko) | 2011-02-04 | 2014-01-23 | 코와 가부시키가이샤 | 녹내장 예방 또는 치료를 위한 약물 요법 |
| US8426471B1 (en) | 2011-12-19 | 2013-04-23 | Topokine Therapeutics, Inc. | Methods and compositions for reducing body fat and adipocytes |
| AU2013347949A1 (en) | 2012-11-21 | 2015-06-11 | Velakine Therapeutics, Inc. | Methods and compositions for locally increasing body fat |
| CN109602691A (zh) | 2013-02-15 | 2019-04-12 | 阿勒根公司 | 持续药物递送植入物 |
| NO2753788T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2013-05-10 | 2018-06-16 | ||
| US9820993B2 (en) | 2013-05-15 | 2017-11-21 | Topokine Therapeutics, Inc. | Methods and compositions for topical delivery of prostaglandins to subcutaneous fat |
| US10188661B2 (en) | 2014-06-27 | 2019-01-29 | Topokine Therapeutics, Inc. | Topical dosage regimen |
| US11285163B2 (en) | 2014-10-20 | 2022-03-29 | Sentiss Pharma Private Limited | Ophthalmic solution |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE7900124L (sv) * | 1978-01-17 | 1979-07-18 | Sandoz Ag | Terapeutisk komposition innehallande prostaglandiner |
| US4254145A (en) * | 1978-08-16 | 1981-03-03 | American Cyanamid Company | Topical application of prostaglandin hypotensive agents |
| US4311707A (en) * | 1979-02-12 | 1982-01-19 | American Cyanamid Company | Process for topically producing cutaneous vasodilation for the treatment of vasospastic or ischemic conditions |
-
1982
- 1982-05-03 US US06/374,165 patent/US4599353A/en not_active Expired - Lifetime
-
1983
- 1983-04-26 AU AU13916/83A patent/AU560189B2/en not_active Expired
- 1983-04-26 DE DE8383104083T patent/DE3369068D1/de not_active Expired
- 1983-04-26 EP EP83104083A patent/EP0093380B1/en not_active Expired
- 1983-04-28 JP JP58076053A patent/JPS591418A/ja active Granted
- 1983-04-29 CA CA000427097A patent/CA1208560A/en not_active Expired
- 1983-05-02 DK DK195083A patent/DK195083A/da not_active Application Discontinuation
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1225168B2 (en) † | 1988-09-06 | 2015-01-21 | Pfizer Health AB | Prostaglandin-F-2 alpha derivative for the treatment of glaucoma or ocular hypertension |
| US8263054B2 (en) | 2002-02-04 | 2012-09-11 | Allergan, Inc. | Method of enhancing hair growth |
| US8298518B2 (en) | 2002-02-04 | 2012-10-30 | Allergan, Inc. | Method of enhancing hair growth |
| US8632760B2 (en) | 2002-02-04 | 2014-01-21 | Allergan, Inc. | Method of enhancing hair growth |
| US8758733B2 (en) | 2002-02-04 | 2014-06-24 | Allergan, Inc. | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists |
| US10188591B2 (en) | 2002-02-04 | 2019-01-29 | Allergan, Inc. | Method of enhancing hair growth |
| US8926953B2 (en) | 2002-02-04 | 2015-01-06 | Allergan, Inc. | Method of enhancing hair growth |
| US8986715B2 (en) | 2002-02-04 | 2015-03-24 | Allergan, Inc. | Method of enhancing hair growth |
| US10159631B2 (en) | 2002-02-04 | 2018-12-25 | Allergan, Inc. | Method of enhancing hair growth |
| US9216183B2 (en) | 2002-02-04 | 2015-12-22 | Allergan, Inc. | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists |
| US9226931B2 (en) | 2002-02-04 | 2016-01-05 | Allergan, Inc. | Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists |
| US9763959B2 (en) | 2009-11-09 | 2017-09-19 | Allergan, Inc. | Compositions and methods for stimulating hair growth |
| US9750750B2 (en) | 2009-11-09 | 2017-09-05 | Allergan, Inc. | Compositions and methods for stimulating hair growth |
| US9849140B2 (en) | 2009-11-09 | 2017-12-26 | Allergan, Inc. | Topical compositions comprising bimatoprost and methods for stimulating hair growth therewith |
| US9149484B2 (en) | 2009-11-09 | 2015-10-06 | Allergan, Inc. | Compositions and methods for stimulating hair growth |
| US8859616B2 (en) | 2011-01-21 | 2014-10-14 | Allergan, Inc. | Compounds and methods for enhancing hair growth |
Also Published As
| Publication number | Publication date |
|---|---|
| AU560189B2 (en) | 1987-04-02 |
| DK195083A (da) | 1983-11-04 |
| US4599353A (en) | 1986-07-08 |
| EP0093380A2 (en) | 1983-11-09 |
| DE3369068D1 (en) | 1987-02-19 |
| DK195083D0 (da) | 1983-05-02 |
| JPH0468288B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1992-11-02 |
| EP0093380A3 (en) | 1984-03-28 |
| EP0093380B1 (en) | 1987-01-14 |
| JPS591418A (ja) | 1984-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1208560A (en) | Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma | |
| Camras et al. | Reduction of intraocular pressure in normal and glaucomatous primate (Aotus trivirgatus) eyes by topically applied prostaglandin F2α | |
| Zhan et al. | Steroid glaucoma: corticosteroid-induced ocular hypertension in cats | |
| JP2726672B2 (ja) | プロスタグランジンとアドレナリン性遮断剤との組合せからなる眼圧降下用組成物 | |
| JPH0643313B2 (ja) | 緑内障の局所治療用組成物 | |
| CN114306331B (zh) | 戊乙奎醚在治疗或预防视力损伤性眼部疾病中的用途 | |
| WO1989010757A1 (en) | New ophthalmic preparation for treating glaucoma | |
| KR100229842B1 (ko) | 지속적 방출형 안과용 제제 | |
| US10688113B2 (en) | Methods of treating eye pain with aminophosphinic derivatives | |
| US5212168A (en) | Method of and solution for treating glaucoma | |
| CA2146006C (en) | Use of ergoline derivatives for the treatment of glaucoma | |
| JP2000506833A (ja) | 斑水腫の治療 | |
| US4594356A (en) | Method for inducing mydriasis in animals | |
| US5266580A (en) | Treatment of low pressure glaucoma and ischemic retinal degeneration with droperidol | |
| RU2434633C2 (ru) | Фармацевтические препаративные формы латрункулина | |
| US6835748B2 (en) | Treatment of ocular disorders | |
| EP0647445B1 (en) | Composition for prophylaxis and treatment of myopia | |
| US5252568A (en) | Treatment of low pressure glaucoma and ischemic retinal degeneration with loxapine | |
| US5252607A (en) | Treatment of low pressure glaucoma and ischemic retinal degeneration | |
| JPH10500130A (ja) | テラゾシンを含有する緑内障治療用医薬組成物 | |
| WO2010129145A2 (en) | Methods and compositions for treating dry eye | |
| WO2025049378A1 (en) | Netarsudil ophthalmological formulations with less toxicity | |
| CA2929965C (en) | Method and composition for treating glaucoma | |
| WO2004096146A2 (en) | Method and composition for preventing, reducing and reversing ocular ischemic neuronal damage | |
| EP0456988B1 (en) | Use of naproxen as mydriatic agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |